^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-DQB1*03:02

    i
    Other names: HLA-DQB1, Major Histocompatibility Complex Class II DQ Beta 1, CELIAC1, HLA-DQB, IDDM1, HLA Class II Histocompatibility Antigen, DQ Beta 1 Chain, MHC Class II Antigen DQB1, MHC Class II HLA-DQ Beta Glycoprotein, MHC Class II Antigen HLA-DQ-Beta-1, MHC Class II DQ Beta Chain
    Entrez ID:
    3119
    Related biomarkers:
    Expression
    Mutation
    8ms
    HLA Gene Polymorphisms in Romanian Patients with Chronic Lymphocytic Leukemia. (PubMed, Genet Res (Camb))
    Correlations between HLA expression and gender showed that women had a higher expression of protective HLA alleles when compared to men. Our data are the first to indicate that in Romanian patients with CLL, the HLA-A∗24:02:01 and HLA-DQA1∗05:05:01 alleles have a protective role against CLL development, whereas HLA-DRB1∗04:02:01 and HLA-DRB3∗02:01:01alleles are positively associated with CLL.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-DQB1*03:02 • HLA-A*24
    almost3years
    HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1). (PubMed, Cancer Sci)
    Eighty-two transplant-ineligible patients with newly diagnosed MM enrolled in a phase II study (JCOG1105) comparing two less intensive melphalan, prednisolone, plus Btz (MPB) regimens were subjected to HLA typing. CR was achieved in patients carrying HLA-DQB1*03:02, -DQB1*05:01, and -DRB1*01:01-class II alleles. HLA genotyping may help predict Btz-induced toxicity and treatment efficacy in patients with MM, although this needs further validation.
    Clinical • Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    HLA-DQB1*03:02 • HLA-DQB1*05:01 • HLA-DRB1*01:01
    |
    bortezomib • melphalan